LAVA Medtech Acquisition Corp. (LVAC) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
303 WYMAN ST STE 300 WALTHAM, MA 02451 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 677 - Blank Checks (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 1,541,231 | |||
| Cash and cash equivalents | 1,541,231 | |||
| Other undisclosed current assets | 658,308 | |||
| Total current assets: | 2,199,539 | |||
| Noncurrent Assets | ||||
| Prepaid expense | 202,948 | |||
| Asset, held-in-trust | 117,876,981 | |||
| Deferred income tax assets | 19,152 | |||
| Total noncurrent assets: | 118,099,081 | |||
| TOTAL ASSETS: | 120,298,620 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 120,234 | |||
| Taxes payable | ✕ | 93,223 | ||
| Accounts payable | 27,011 | |||
| Accrued liabilities | ||||
| Deferred compensation liability | ||||
| Derivative instruments and hedges, liabilities | ||||
| Due to related parties | ||||
| Total current liabilities: | 120,234 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 4,751,500 | |||
| Due to related parties | 10,000 | |||
| Derivative instruments and hedges, liabilities | 4,741,500 | |||
| Other undisclosed noncurrent liabilities | 4,025,000 | |||
| Total noncurrent liabilities: | 8,776,500 | |||
| Total liabilities: | 8,896,734 | |||
| Temporary equity, carrying amount | 117,875,000 | |||
| Equity | ||||
| Equity, attributable to parent, including: | (6,473,114) | |||
| Accumulated deficit | (6,473,401) | |||
| Other undisclosed equity, attributable to parent | 287 | |||
| Total equity: | (6,473,114) | |||
| TOTAL LIABILITIES AND EQUITY: | 120,298,620 | |||
Income Statement (P&L) (USD)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Operating expenses | |||
| Other operating expense, net (Other Expenses) | |||
| Operating loss: | |||
| Nonoperating income | |||
| Investment income, nonoperating | |||
| Interest and debt expense | |||
| Income from continuing operations before equity method investments, income taxes: | |||
| Other undisclosed income from continuing operations before income taxes | |||
| Income from continuing operations before income taxes: | |||
| Income tax expense | (19,152) | ||
| Income (loss) from continuing operations: | (19,152) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (19,152) | |
| Net income (loss) attributable to parent: | (19,152) | ||
| Preferred stock dividends and other adjustments | |||
| Net income (loss) available to common stockholders, diluted: | (19,152) | ||
Comprehensive Income (USD)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Net income (loss): | (19,152) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (19,152) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.